journal contribution posted on 2023-04-04, 02:04 authored by Evelien Schaafsma, Walburga Croteau, Mohamed ElTanbouly, Elizabeth C. Nowak, Nicole C. Smits, Jie Deng, Aurelien Sarde, Cecilia A. Webber, Dina Rabadi, Chao Cheng, Randolph Noelle, J. Louise Lines
Additional data supporting Figure 3. (A) Pathway enrichment for each cluster described in figure 3. (B) Comparison of myeloid clusters from this study with those identified by . Dots represent the proportion of myeloid clusters described in this study (bottom) in the Gubin et al. myeloid clusters (left). Each row is normalized by row sums. Cluster identity from  was obtained from the original publication. (C) Cluster frequencies as a proportion of the myeloid infiltrate in I/V or CP/CPV treatment.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
United States Department of Health and Human ServicesFind out more...
Division of Cancer Epidemiology and Genetics, National Cancer Institute (DCEG)
Center for Biomedical Informatics and Information Technology, National Cancer Institute (CBIIT)
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (DMID)
Cancer Prevention and Research Institute of Texas (CPRIT)
ARTICLE ABSTRACTV domain immunoglobulin suppressor of T-cell activation (VISTA) is a premier target for cancer treatment due to its broad expression in many cancer types and enhanced expression upon development of adaptive immune checkpoint resistance. In the CT26 colorectal cancer model, monotherapy of small tumors with anti-VISTA resulted in slowed tumor growth. In a combination therapy setting, large CT26 tumors showed complete adaptive resistance to anti–PD-1/CTLA-4, but inclusion of anti-VISTA led to rejection of half the tumors. Mechanisms of enhanced antitumor immunity were investigated using single-cell RNA sequencing (scRNA-seq), multiplex image analysis, and flow cytometry of the tumor immune infiltrate. In both treatment models, anti-VISTA upregulated stimulated antigen presentation pathways and reduced myeloid-mediated suppression. Imaging revealed an anti-VISTA stimulated increase in contacts between T cells and myeloid cells, further supporting the notion of increased antigen presentation. scRNA-seq of tumor-specific CD8+ T cells revealed that anti-VISTA therapy induced T-cell pathways highly distinct from and complementary to those induced by anti–PD-1 therapy. Whereas anti–CTLA-4/PD-1 expanded progenitor exhausted CD8+ T-cell subsets, anti-VISTA promoted costimulatory genes and reduced regulators of T-cell quiescence. Notably, this is the first report of a checkpoint regulator impacting CD8+ T-cell quiescence, and the first indication that quiescence may be a target in the context of T-cell exhaustion and in cancer. This study builds a foundation for all future studies on the role of anti-VISTA in the development of antitumor immunity and provides important mechanistic insights that strongly support use of anti-VISTA to overcome the adaptive resistance seen in contemporary treatments involving PD-1 and/or CTLA-4.See related Spotlight by Wei, p. 3